Egetis Therapeutics AB (publ) (-0ABW), the Stockholm-headquartered rare disease pharmaceutical company, has received a public cash offer from U.S.-listed ANI Pharmaceuticals, Inc. (ANIP) valuing the transaction at approximately SEK 5,304 million. The offer of SEK 11.25 per share represents a premium of approximately 48.0 percent to Egetis' volume-weighted average price over the last 180 trading days. The Board of Directors unanimously recommends that shareholders accept the offer, citing ANI's established rare disease commercialisation platform and the opportunity to accelerate the U.S. launch of EMCITATE.

Key Points

  • Egetis Therapeutics AB (publ) (-0ABW), listed on Nasdaq Stockholm
  • ANI Pharmaceuticals has made a public cash offer of SEK 11.25 per Egetis share, with a total offer value of approximately SEK 5,304 million
  • Acceptance period expected to run from on or around 20 November 2026 to on or around 18 December 2026, with settlement expected on or around 29 December 2026
  • Investors should watch whether the 90 percent acceptance threshold is met and whether any competing offer emerges before the December deadline

ANI Pharmaceuticals Offers SEK 11.25 Per Share With a 12.6% Premium to Last Closing Price

ANI Pharmaceuticals, a Delaware-incorporated company listed on the Nasdaq Global Market, has launched a public cash offer to acquire all shares, convertible loan instruments, and warrants in Egetis. The offer price of SEK 11.25 per share represents a premium of approximately 12.6 percent to the closing price of SEK 9.99 on 4 November 2026, the last trading day before announcement. ANI will also pay SEK 65,750,817 for the EUR 3 million principal amount of the convertible loan and SEK 6.99 per warrant. ANI has confirmed it will not increase the offer price unless a competing proposal emerges.

EMCITATE U.S. FDA Approval Underpins the Strategic Rationale for the Egetis Acquisition

Egetis' lead product, EMCITATE (tiratricol), received U.S. Food and Drug Administration approval on 28 September 2026 as the first and only approved treatment for MCT8 deficiency, a rare and life-shortening genetic disorder also known as Allan–Herndon–Dudley syndrome. EMCITATE already holds marketing authorisations in the European Union. The Board highlighted that combining ANI's U.S. rare disease commercialisation infrastructure with Egetis' product could broaden patient access beyond what a standalone U.S. commercial build-out would achieve, noting execution risk of an independent launch as a key consideration in recommending the offer.

Shareholders Representing 42.2% of Egetis Shares Have Already Committed to Accept the Offer

Six existing shareholders — Frazier Life Sciences, Cidro Förvaltning AB, Cetoros AB, Avla Holding AB, The Invus Group, and RegulaPharm AB — holding in aggregate 196,127,092 shares, representing approximately 42.2 percent of outstanding ordinary shares, have entered into irrevocable undertakings to accept the offer. These undertakings are conditional, including a provision that they would lapse if a competing offer exceeding the ANI price by more than five percent is announced and ANI does not match it. Completion remains subject to ANI acquiring shares representing more than 90 percent of Egetis on a fully diluted basis, alongside necessary regulatory clearances.

Competitive Process and Board Assessment Support the Unanimous Recommendation

The Board noted the offer resulted from a competitive process initiated following an unsolicited, non-binding indicative acquisition proposal received in the third quarter of 2026, supported by financial adviser Centerview Partners LLC, with Advokatfirman Vinge serving as legal adviser. ANI conducted confirmatory due diligence and received certain preliminary financial information relating to Egetis' third-quarter 2026 results, which the company stated would be published separately. ANI communicated no intention to make material changes to operations, business locations, or employee terms, and the Board stated it had no reason to question those assurances.